| What Lies Ahead for Javelin Pharmaceuticals? CVTrader submits:Javelin Pharmaceuticals (JAV) is a specialty pharmaceutical company with a focus in the pain management market. Their primary technical innovations are improved formulations of existing drugs. Javelin has one marketed product - Dyloject - in the UK. In the US, it has submitted a New Drug Application (NDA) for Dyloject and has two drug candidates in Phase III clinical development: Ereska (intranasal ketamine) and Rylomine (intranasal morphine). Its stock price has been in wild swings in the last several months because of its involvement in two M/A activities. Late last December, Myriad Pharmaceuticals (MYRX) entered into an agreement to merger with Javelin. But in April shortly before the closing date, Javelin struck a better deal with Hospira (HSP) for an all-cash acquisition of $2.20 per share (~$145M in value with a ~60% premium over its closing price). However, things are not all rosy from there for Javelin share holders. On May 19th, Hospira announced that it is extending the tender offer for another 2 weeks because certain conditions were not fully satisfied prior to the expiration of the initial offering period. Understandably, Javelin's stock price dropped ~40% at the start of the day. But that's not all; five days later, Javelin announced that its UK partner, Therabel Pharma which licensed the commercial rights to Dyloject in the European Union, is withdrawing the product from the UK market because of the presence of a white particulate matter in some vials of Dyloject in its supply chain. It appears to be a bigger blow to Javelin and its stock price dropped to as low as $1.15, but it soon bounced back to as high as $1.77 the day before the deadline of the extended tender offer.Complete Story » seekingalpha.com |
The Salt Hiding in Your Diet Adults consume more salt than recommended. Now, officials want us to eat even less. That's easier said than done, in part because people often don't know it's in their food. online.wsj.com |
Deli Meats Sold to Wal-Mart Recalled A subsidiary of Tyson Foods is recalling 380,000 pounds of deli meats that may be contaminated with bacteria. online.wsj.com |
Cleveland BioLabs' Unfounded Fear of Dilution M.E. Garza submits: The last time shares of Cleveland Biolabs (CBLI) went on a run like they've seen the past few weeks, the company hit shareholders with news that it was raising money, and diluting shares. You can't blame cautious investors for over-reacting to news three days ago that the Company had filed a registration to "sell, from time to time, up to 7,808,859 shares of Common Stock on behalf of Selling Shareholders." After the news, the stock price declined 4.57%, but if the language used in these legal filings were written in plain english, investors would have realized that this filing is not indicative of future dillution. This is a smart company making sure that anyone holding a Series B Class of Warrants that were issued in a private placement back in 2007 has to pay if they want to sell them now that the stock is trading above $5.99. If the Company hadn't filed this registration, then theoretically, the shares underlying these warrants could be sold at a higher price (hint: much higher prices are expected) without direct proceeds to the Company.Complete Story » seekingalpha.com |
Hank Aaron Gets Back in the Game - Video Baseball Legend Hank Aaron Encourages People Struggling with Osteoarthritis of the Knee to Get Back in the Game feedproxy.google.com |